- Home
- UBX vs HOOK Comparison
UBX vs HOOK Comparison
Compare UBX & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- HOOK
- Stock Information
- Founded
- UBX 2009
- HOOK 2011
- Country
- UBX United States
- HOOK United States
- Employees
- UBX N/A
- HOOK N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- UBX Health Care
- HOOK Health Care
- Exchange
- UBX Nasdaq
- HOOK Nasdaq
- Market Cap
- UBX 29.2M
- HOOK 24.5M
- IPO Year
- UBX 2018
- HOOK 2019
- Fundamental
- Price
- UBX $2.22
- HOOK $1.86
- Analyst Decision
- UBX Strong Buy
- HOOK Buy
- Analyst Count
- UBX 2
- HOOK 4
- Target Price
- UBX $7.00
- HOOK $10.67
- AVG Volume (30 Days)
- UBX 483.8K
- HOOK 229.2K
- Earning Date
- UBX 11-04-2024
- HOOK 03-21-2025
- Dividend Yield
- UBX N/A
- HOOK N/A
- EPS Growth
- UBX N/A
- HOOK N/A
- EPS
- UBX N/A
- HOOK N/A
- Revenue
- UBX N/A
- HOOK $49,999,000.00
- Revenue This Year
- UBX N/A
- HOOK $148.80
- Revenue Next Year
- UBX $33.62
- HOOK N/A
- P/E Ratio
- UBX N/A
- HOOK N/A
- Revenue Growth
- UBX N/A
- HOOK 143.30
- 52 Week Low
- UBX $0.94
- HOOK $1.72
- 52 Week High
- UBX $3.10
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- UBX 61.12
- HOOK 42.90
- Support Level
- UBX $2.02
- HOOK $1.90
- Resistance Level
- UBX $2.42
- HOOK $2.08
- Average True Range (ATR)
- UBX 0.31
- HOOK 0.16
- MACD
- UBX 0.01
- HOOK 0.02
- Stochastic Oscillator
- UBX 39.61
- HOOK 38.61
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.